13F reference period
Q3 2026
Security Snapshot
Monopar Therapeutics - Common Stock (MNPR) Institutional Ownership
CUSIP: 61023L207
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
36
Shares (Excl. Options)
1.38M
Full value: 1,383,556 · shares · 30 Sep 2026Price
$79.67
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- MNPR on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 1,383,556
- Total 13F value
- $110,267,869
- Portfolio coverage rank
- 0%
- Share change
- +222,899
- Value change
- +$16,778,426
- Number of holders
- 36
- Shares outstanding
- 6,722,326
- SEC-reported price per share
- $79.67
- Insider filing price
- $79.67
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- MNPR - Monopar Therapeutics - Common Stock is tracked under CUSIP 61023L207.
- 36 institutions reported positions in Q3 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 95 to 36 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$576.14M
Full value: $576,138,985 · USD · 30 Jun 2026.$110.27M
Full value: $110,267,869 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 36 institutions filings for Q3 2026.
Security key
61023L207
13F reference period
Q3 2026
13F holders
36
13D/G owners
7
CIK / CUSIP context first
Open Q3 2026 holders
MNPR full holder history
Monopar Therapeutics SEC filings
Monopar Therapeutics company facts
Monopar Therapeutics insider transactions
Monopar Therapeutics 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61023L207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
MNPR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 20% | +1.6% | $105,138,701 | +$9,391,992 | 1,287,368 | +9.8% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| Monopar Therapeutics | 13% | $31,414,229 | 704,829 | Hendricks Diane | 09 Dec 2024 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $43,402,756 | -$4,890,637 | 667,632 | -10% | RA Capital Management, L.P. | 31 Dec 2025 |
| ASTRAZENECA PLC | 7.8% | $34,126,392 | 522,667 | AstraZeneca PLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 5% | $26,937,940 | 338,133 | BlackRock, Inc. | 30 Sep 2026 | |||
| Adage Capital Management, L.P. | 4.8% | -24% | $31,485,818 | -$9,712,000 | 324,195 | -24% | Adage Capital Management, L.P. | 30 Jun 2026 |
| Saturn V Capital Management LP | 4.7% | -10% | $30,435,854 | -$3,131,343 | 313,384 | -9.3% | Saturn V Capital Management LP | 30 Jun 2026 |
As of 30 Sep 2026,
36
institutional investors reported holding
shares of
Monopar Therapeutics - Common Stock (MNPR).
This represents
21%
of the company’s total
outstanding shares.
1.38M
Full value: 1,383,556 · shares · 30 Sep 20266.72M
Full value: 6,722,326 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
21%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Siren, L.L.C. | 4% | 270,118 | 0% | 0.51% | $21,520,301 |
| STATE STREET CORP | 3.4% | 229,771 | +148% | 0% | $18,305,856 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 217,958 | +3.9% | 0% | $17,364,714 |
| Candriam S.C.A. | 1.9% | 129,797 | -9.4% | 0.05% | $10,378,709 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 119,852 | +6.5% | 0% | $9,550,731 |
| Quadrature Capital Ltd | 1.4% | 92,499 | 0.05% | $7,369,395 | |
| Vivo Capital, LLC | 1.3% | 90,500 | 0% | 0.79% | $7,210,135 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.64% | 42,832 | -12% | 0% | $3,412,425 |
| MORGAN STANLEY | 0.57% | 38,037 | +112% | 0% | $3,030,466 |
| Qube Research & Technologies Ltd | 0.55% | 37,213 | 0% | $2,964,760 | |
| VANGUARD FIDUCIARY TRUST CO | 0.47% | 31,441 | +11% | 0% | $2,504,904 |
| DEUTSCHE BANK AG\ | 0.38% | 25,461 | -18% | 0% | $2,028,477 |
| BNP PARIBAS FINANCIAL MARKETS | 0.12% | 8,018 | 0% | $638,794 | |
| Creative Planning | 0.12% | 7,977 | +2.7% | 0% | $635,527 |
| Rafferty Asset Management, LLC | 0.09% | 5,959 | 0% | $474,754 | |
| Magnetar Financial LLC | 0.09% | 5,777 | 0% | $460,254 | |
| AMERICAN CENTURY COMPANIES INC | 0.08% | 5,606 | +127% | 0% | $446,630 |
| GERBER, LLC | 0.08% | 5,601 | 0% | 0.2% | $446,232 |
| Virtus Investment Advisers, LLC | 0.08% | 5,309 | -3% | 0.09% | $422,968 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0.08% | 5,300 | 0% | 0% | $422,251 |
| AXQ CAPITAL, LP | 0.04% | 2,566 | 0.03% | $204,433 | |
| Vanguard Global Advisers, LLC | 0.03% | 1,845 | +19% | 0% | $146,991 |
| MEEDER ASSET MANAGEMENT INC | 0.02% | 1,651 | +19% | 0.01% | $131,535 |
| Police & Firemen's Retirement System of New Jersey | 0.02% | 1,121 | -24% | 0% | $89,310 |
| NewEdge Advisors, LLC | 0.01% | 600 | 0% | 0% | $47,802 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,383,556 | $110,267,869 | +$16,778,426 | $79.67 | 36 |
| 2026 Q2 | 6,222,200 | $576,138,985 | +$12,650,456 | $92.59 | 95 |
| 2026 Q1 | 6,235,981 | $341,548,688 | +$37,301,460 | $54.79 | 82 |
| 2025 Q4 | 5,529,904 | $360,987,109 | +$75,159,494 | $65.30 | 74 |
| 2025 Q3 | 4,336,026 | $354,298,233 | +$99,764,618 | $81.67 | 55 |
| 2025 Q2 | 3,176,497 | $113,304,454 | +$10,313,028 | $35.78 | 43 |
| 2025 Q1 | 2,886,019 | $109,374,138 | +$11,536,779 | $36.41 | 34 |
| 2024 Q4 | 2,578,295 | $57,125,546 | +$56,777,792 | $22.00 | 18 |
| 2024 Q3 | 15,707 | $105,865 | +$105,865 | $6.74 | 6 |